Among 545 patients aged 75 or older admitted to an acute geriatric ward, receiving statin therapy on day 2 of hospitalisation was associated with a 49% reduction in adjusted odds of in-hospital all-cause mortality (OR 0.51, 95% CI 0.3–1.0) and a 6.3% absolute risk reduction. Critically, benefits were comparable whether patients had prior atherosclerotic cardiovascular disease or not (OR 0.5 vs 0.6), suggesting mechanisms beyond lipid-lowering — possibly statins' pleiotropic anti-inflammatory effects — may be driving the signal.
This finding is provocative precisely because it challenges the clinical inertia around deprescribing statins in frail elderly inpatients, a practice increasingly common under "goals of care" frameworks. The survival benefit appearing independent of cardiovascular history aligns with emerging evidence that statins modulate systemic inflammation — potentially relevant during acute illness when inflammatory cascades accelerate organ dysfunction. However, several important limitations constrain interpretation. The retrospective observational design cannot exclude confounding by indication: patients well enough to continue statins may simply be less critically ill than those in whom statins were withheld or never prescribed. The cohort of 545 is modest, confidence intervals brush statistical significance, and a single Belgian centre limits generalisability. Handgrip strength adjustment is a reasonable frailty proxy but imperfect. This is best characterised as hypothesis-generating rather than practice-changing — a credible signal that should accelerate the prospective randomised trials the authors themselves call for.